SCHEMBL3191209

SCHEMBL3191209

Cc1nn(-c2c(Cl)cc(C(F)(F)F)cc2Cl)c(Cl)c1C=NC(C#N)=C(N)C#N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
KMT2A Q03164 2/20 0.42
GABRB3 P28472 14/20 0.40
GABRA2 P47869 12/20 0.40
GABRB2 P47870 12/20 0.40
GABRP O00591 11/20 0.40
GABRD O14764 11/20 0.40
GABRA1 P14867 11/20 0.40
GABRB1 P18505 11/20 0.40
GABRG2 P18507 11/20 0.40
GABRA5 P31644 11/20 0.40
GABRA3 P34903 11/20 0.40
GABRA4 P48169 11/20 0.40
GABRE P78334 11/20 0.40
GABRA6 Q16445 11/20 0.40
GABRG1 Q8N1C3 11/20 0.40
GABRG3 Q99928 11/20 0.40
GABRQ Q9UN88 11/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
NR1I2 O75469 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5245692 1.00 LMNA (0.42) LMNAKMT2AGABRB3GABRA2GABRB2
SCHEMBL9218268 0.92 GABRB3 (0.42) LMNAKMT2AGABRB3GABRA2GABRB2
SCHEMBL9218260 0.92 GABRB3 (0.42) LMNAKMT2AGABRB3GABRA2GABRB2
SCHEMBL9216331 0.91 GABRP (0.46) LMNAGABRB3GABRA2GABRB2GABRP
SCHEMBL9504165 0.89 GABRB3 (0.38) LMNAKMT2AGABRB3GABRA2GABRB2
SCHEMBL9504169 0.89 GABRB3 (0.38) LMNAKMT2AGABRB3GABRA2GABRB2
SCHEMBL9502977 0.88 GABRA2 (0.39) LMNAGABRB3GABRA2GABRB2GABRP
SCHEMBL9502983 0.88 GABRA2 (0.39) LMNAGABRB3GABRA2GABRB2GABRP
SCHEMBL9704872 0.84 GABRP (0.44) LMNAGABRB3GABRA2GABRB2GABRP
SCHEMBL9704876 0.84 GABRP (0.44) LMNAGABRB3GABRA2GABRB2GABRP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678923-B2 Method for synthesizing 5-chloro-1-aryl-4-(4,5-dicyano-1h-imidazol-2-yl)-3-alkyl-1h-pyrazole derivatives EVULTIS (CH) 2010-03-16 US disclosed
US-20070155811-A1 Method for synthesing 5-chloro-1-aryl-4-(4,5-dicyano-1h-imidazol-2-yl)-3-alkyl-1h-pyrazole derivatives EVULTIS (CH) 2007-07-05 US disclosed
EP-1618104-B1 METHOD FOR SYNTHESISING 5-CHLORO-1-ARYL-4-(4, 5-DICYANO-1H-IMIDAZOL-2-YL)-3-ALKYL-1H-PYRAZOLE DERIVATIVES EVULTIS (CH) 2007-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155811-A1 Method for synthesing 5-chloro-1-aryl-4-(4,5-dicyano-1h-imidazol-2-yl)-3-alkyl-1h-pyrazole derivatives CYP3A5, CYP4B1, AADAC LMNA 2504/4885KMT2A 1818/4885GABRB3 1154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.